Exact Sciences Corp Stock Price, News & Analysis

Exact Sciences Corp. (NASDAQ: EXAS) reported promising data for its second-generation Cologuard test, achieving an overall sensitivity of 95.2% for colorectal cancer with a specificity of 92.4%. The test demonstrated 83.3% sensitivity for high-grade dysplasia and 57.2% for advanced precancerous lesions. The findings will be presented at ASCO GI on January 22. If successful, the new Cologuard could enhance screening rates and reduce unnecessary follow-up colonoscopies. A pivotal trial is ongoing, with results expected late 2022 or early 2023.

Exact Sciences Corp. (NASDAQ: EXAS) has acquired PreventionGenetics, a genetic testing laboratory, for $190 million to enhance its cancer diagnostics portfolio and expand into hereditary cancer testing (HCT). The acquisition aims to leverage PreventionGenetics' expertise and technology to improve patient access to HCT, helping individuals understand their cancer risks. With expected 2021 revenue of $36 million, the acquisition strengthens Exact Sciences' presence in the genetics realm, tapping into a network of nearly 300,000 healthcare providers.

Exact Sciences Corp. (Nasdaq: EXAS) announced estimated fourth quarter 2021 revenue between $472 million and $475 million, reflecting a 2% increase year-over-year. Excluding COVID-19 testing, revenue grew 16%. Screening revenue is projected at $277 million to $278 million (up 11%), while Precision Oncology revenue is estimated at $148.5 million to $149.5 million (up 27%). However, COVID-19 testing revenue fell by 53%. The company aims for strong growth in cancer detection services.

Exact Sciences Corp. (NASDAQ: EXAS) has entered an exclusive licensing agreement with OncXerna Therapeutics to offer the innovative Xerna TME Panel lab services to U.S. patients. This tumor microenvironment panel aids in predicting patient responses to immunotherapies, enhancing therapy selection for oncologists. The integration with Exact Sciences’ GEM ExTra test promises to improve patient outcomes by providing deeper insights into treatment efficacy. The Xerna TME Panel remains investigational and has not yet received FDA approval.

Amberstone Biosciences has successfully completed a $12 million Series A financing round, led by Viva BioInnovator, Co-win Ventures, and Sinovation Ventures, among others. The funds will be utilized to advance their tumor microenvironment activated therapeutic programs to the investigational new drug application (IND) enabling stage. CEO George Wu expressed gratitude for investor support, emphasizing their goal of developing safer and more effective therapies for cancer patients.

Exact Sciences Corp. (NASDAQ: EXAS) announced its participation in the J.P. Morgan Healthcare Conference, scheduled for January 12, 2022, at 5:15 p.m. ET. During the event, company management will deliver a presentation followed by a Q&A session. Investors can access the live webcast on Exact Sciences' website.

Exact Sciences focuses on cancer screening and diagnostics and continues to develop its product pipeline, including Cologuard and Oncotype DX, to combat deadly cancers.

Exact Sciences Corp. (NASDAQ: EXAS) presented new data at the 2021 San Antonio Breast Cancer Symposium (SABCS) showcasing the clinical significance of the Oncotype DX Breast Recurrence Score test. Notably, findings from the RxPONDER study reaffirmed that postmenopausal women with Recurrence Score results of 0-25 do not benefit from adjuvant chemotherapy. Additionally, a new 16-gene radiation therapy signature was introduced, indicating potential to identify early-stage breast cancer patients who might skip irradiation after surgery. The data aims to enhance personalized treatment approaches for breast cancer patients.

Exact Sciences Corp. (EXAS) announced the publication of the RxPONDER trial results in The New England Journal of Medicine. This independent study shows that postmenopausal women with 1 to 3 positive lymph nodes and Oncotype DX Breast Recurrence Score results of 0 to 25 can safely avoid chemotherapy, which spares them from its side effects. The updated NCCN Guidelines now recognize the Oncotype DX test as the only tool for predicting chemotherapy benefit in early-stage breast cancer, potentially impacting treatment for tens of thousands of patients globally.

Exact Sciences Corp. (NASDAQ: EXAS) announced significant findings from a study published in Urologic Oncology, highlighting that adverse pathology in low-risk prostate cancer patients is a strong predictor of worse outcomes. The study involving 428 patients revealed those with adverse pathology were 10 times more likely to develop metastatic disease and eight times more likely to die from prostate cancer. The Oncotype DX Genomic Prostate Score test, designed to assess risk beyond clinical factors, has shown clinical utility in guiding treatment decisions. New tailored patient reports will be launched in December 2021.